Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Pamela R. Kushner"'
Publikováno v:
Advances in Therapy. 40:2869-2885
Publikováno v:
Clinical Diabetes. 40:401-412
Individuals with type 2 diabetes are at increased risk of both renal and cardiovascular events. The convergence of type 2 diabetes, chronic kidney disease, and cardiovascular disease, including heart failure, requires management by a multidisciplinar
Autor:
Yehuda Handelsman, Javed Butler, George L. Bakris, Ralph A. DeFronzo, Gregg C. Fonarow, Jennifer B. Green, George Grunberger, James L. Januzzi, Samuel Klein, Pamela R. Kushner, Darren K. McGuire, Erin D. Michos, Javier Morales, Richard E. Pratley, Matthew R. Weir, Eugene Wright, Vivian A. Fonseca
Publikováno v:
Journal of Diabetes and its Complications. 37:108389
Autor:
Pamela R. Kushner, Davida F. Kruger
Publikováno v:
Clin Diabetes
Continuous glucose monitoring (CGM) provides comprehensive assessment of daily glucose measurements for patients with diabetes and can reveal high and low blood glucose values that may occur even when a patient’s A1C is adequately controlled. Among
Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care
Publikováno v:
Postgraduate Medicine. 132:305-313
Use of continuous glucose monitoring (CGM) improves clinical outcomes in type 1 diabetes, and significant benefits been demonstrated in patients with type 2 diabetes, including improved glycemic control, better treatment adherence, and an increased u
Autor:
Salvatore Barone, Supriya Kumar, Pamela R. Kushner, Hungta Chen, Krister Järbrink, Eric Wittbrodt, Alyshah Abdul Sultan
Publikováno v:
Diabetes. 70
Autor:
Johannes Nolte, Francesc Xavier Cos, Pamela R. Kushner, Gary F. Deed, Stephen Brunton, Peter J. Lin, Naresh Kanumilli
Publikováno v:
Diabetes. 69
Background: Despite recent recommendations for the use of glucose-lowering therapies with additional cardiovascular (CV) and renal benefits, as demonstrated through CV outcomes trials (CVOTs), many patients (pts) with type 2 diabetes mellitus (T2D) m
Autor:
Xavier Cos, Gary Deed, Peter J. Lin, Stephen Brunton, Pamela R. Kushner, Johannes Nolte, Naresh Kanumilli
Publikováno v:
Journal of Diabetes and its Complications. 35:107813
Aim To explore reasons behind treatment inertia in current approaches to early cardiorenal risk management in type 2 diabetes (T2D). Methods A global, web-based, quantitative panel survey of primary care physicians (PCPs) and primary care diabetes sp
Autor:
Pamela R. Kushner
Publikováno v:
Women's Health
Sodium–glucose co-transporter 2 (SGLT2) inhibitors, such as canagliflozin, are used in patients with Type 2 diabetes mellitus (T2DM). In clinical studies, canagliflozin significantly reduced A1C, bodyweight and blood pressure, and was generally wel
Autor:
Pamela R, Kushner
Publikováno v:
The Journal of family practice. 65
Traditional measures of overall glucose control, such as glycated hemoglobin (A1C), may not fully capture short-term, rapid changes in blood glucose. With the availability of multiple options to control A1C, glycemic fluctuations have emerged as an a